Can thiazolidinediones delay disease progression in type 2 diabetes?

References

• Leiter LA, Barr A, Belanger A, et al. Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care 2001;24:1038–43
   PubMed Web of Science ®Google Scholar
• Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004;109: 1101–7
   Google Scholar
• Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3–19
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854–65
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44: 1249–58
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• Dormandy JA, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–89
   PubMed Web of Science ®Google Scholar
• Viberti G, Kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737–43
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S, Holman R, et al. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004;47:1519–27
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Brindisi MC, Rabasa-Lhoret R. The prevention of type 2 diabetes: what is the evidence? Minerva Endocrinol 2005;30: 179–91
   Google Scholar
• Simpson RW, Shaw JE, Zimmet PZ. The prevention of type 2 diabetes – lifestyle change or pharmacotherapy? A challenge for the 21st century. Diabetes Res Clin Pract 2003;59: 165–80
   Google Scholar
• Robertson RP, Harmon J, Tran PO, et al. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004;53(Suppl 1):S119–S124
   PubMedGoogle Scholar
• Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365: 1333–46
   Google Scholar
• Donath MY, Ehses JA, Maedler K, et al. Mechanisms of β-cell death in type 2 diabetes. Diabetes 2005;54(Suppl 2):S108–13
   PubMed Web of Science ®Google Scholar
• Donath MY, Størling J, Maedler K, et al. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 2003;81:455–70
   PubMed Web of Science ®Google Scholar
• Hull RL, Westermark GT, Westermark P, et al. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004;89:3629–43
   PubMed Web of Science ®Google Scholar
• Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52: 102–10
   Google Scholar
• Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001;50:1021–9
   Google Scholar
• Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280–8
   PubMed Web of Science ®Google Scholar
• Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413–23
   PubMed Web of Science ®Google Scholar
• Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002;32(Suppl 3):35–45
   Google Scholar
• Pfeifer MA, Halter JB, Porte DJ. Insulin secretion in diabetes mellitus. Am J Med 1981;70:579–88
   Google Scholar
• Kahn SE. Regulation of b-cell function in vivo: from health to disease. Diabetes Rev 1996;4:372–89
   Google Scholar
• Weiss R, Caprio S, Trombetta M, et al. Beta-cell function across the spectrum of glucose tolerance in obese youth. Diabetes 2005;54:1735–43
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Fritsche A, Stefan N, et al. Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction. J Clin Endocrinol Metab 2001;86:1235–9
   PubMed Web of Science ®Google Scholar
• Fritsche A, Madaus A, Stefan N, et al. Relationships among age, proinsulin conversion, and beta-cell function in nondiabetic humans. Diabetes 2002;51(Suppl 1):S234–9
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Meigs JB, et al. Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women. Am J Med 2003;114:438–44
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710–9
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabetic Med 2000;17:40–7
   PubMed Web of Science ®Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study [The Pioglitazone 027 Study Group]. Clin Ther 2000;22:1395–409
   PubMed Web of Science ®Google Scholar
• Jones TA, Sautter M, Van Gaal LF, et al. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003;5:163–70
   PubMed Web of Science ®Google Scholar
• Smith SA, Porter LE, Biswas N, et al. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin: insulin ratio in type 2 diabetes. J Clin Endocrinol Metab 2004;89:6048–53
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Roden M, Urquhart R, et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia 2005;48:553–60
   PubMed Web of Science ®Google Scholar
• Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000;355:1008–10
   PubMed Web of Science ®Google Scholar
• Ye JM, Dzamko N, Cleasby ME, et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 2004;47:1306–13
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Schondorf T, Seidel D, et al. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism 2006;55:20–5
   PubMed Web of Science ®Google Scholar
• Shimizu H, Oh I, Tsuchiya T, et al. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study. Diabetic Med 2006;23:253–7
   PubMed Web of Science ®Google Scholar
• Samaha FF, Szapary PO, Iqbal N, et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26:624–30
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 2000;24(Suppl 4):S23–7
   PubMed Web of Science ®Google Scholar
• Holman RR, Kahn SE, Heise MA, et al. Levels of b-cell dysfunction and insulin resistance differ between Europeans and North Americans with recently-diagnosed diabetes in the ADOPT study. Diabetologia 2003;46(Suppl 2):A198
   Google Scholar
• Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. Q J Med 2003;96:281–8
   Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
   PubMed Web of Science ®Google Scholar
• Lindstrom J, Eriksson JG, Valle TT, et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention study: results from a randomized clinical trial. J Am Soc Nephrol 2003;14(Suppl 2):S108–13
   PubMedGoogle Scholar
• Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289–97
   PubMed Web of Science ®Google Scholar
• Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance [The Da Qing IGT and Diabetes Study]. Diabetes Care 1997;20:537–44
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–50
   PubMed Web of Science ®Google Scholar
• Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes 2005;54:2404–14
   PubMed Web of Science ®Google Scholar
• Rimm EB, Chan J, Stampfer MJ, et al. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ 1995;310:555–9
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Shaper AG, Perry IJ. Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men. Diabetes Care 2001;24: 1590–5
   Google Scholar
• Will JC, Galuska DA, Ford ES, et al. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. Int J Epidemiol 2001;30:540–6
   PubMed Web of Science ®Google Scholar
• Patja K, Jousilahti P, Hu G, et al. Effects of smoking, obesity and physical activity on the risk of type 2 diabetes in middle-aged Finnish men and women. J Intern Med 2005;258: 356–62
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072–7
   PubMed Web of Science ®Google Scholar
• Knowler WC, Hamman RF, Edelstein SL, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150–6
   PubMed Web of Science ®Google Scholar
• Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796–803
   PubMed Web of Science ®Google Scholar
• Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517–22
   PubMed Web of Science ®Google Scholar
• Cavaghan MK, Ehrmann DA, Byrne MM, et al. Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997;100:530–7
   PubMed Web of Science ®Google Scholar
• Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188–93
   PubMed Web of Science ®Google Scholar
• Bennett SM, Agrawal A, Elasha H, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabetic Med 2004;21:415–22
   PubMed Web of Science ®Google Scholar
• Durbin RJ. Thiazolidinedione therapy in the prevention/ delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004;6:280–5
   PubMed Web of Science ®Google Scholar
• Leiter LA, Lewanczuk RZ. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition. Am J Hypertens 2005;18:121–8
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [The Heart Outcomes Prevention Evaluation Study Investigators]. N Engl J Med 2000;342:145–53
   PubMed Web of Science ®Google Scholar